Ruilope LM - Search Results

1

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Agarwal R, et al. Among authors: ruilope lm. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777. Eur Heart J. 2022. PMID: 35023547 Free PMC article. Clinical Trial.

2

Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.

Ruilope LM, Usan L, Segura J, Bakris GL. Ruilope LM, et al. J Hypertens. 2004 Jan;22(1):217-22. doi: 10.1097/00004872-200401000-00032. J Hypertens. 2004. PMID: 15106814 Clinical Trial.

3

Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients.

Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, Ruilope LM. Segura J, et al. Among authors: ruilope lm. J Am Soc Nephrol. 2004 Jun;15(6):1616-22. doi: 10.1097/01.asn.0000127045.14709.75. J Am Soc Nephrol. 2004. PMID: 15153573

4

Development of chronic kidney disease in essential hypertension during long-term therapy.

Segura J, Campo C, García-Donaire JA, Ruilope LM. Segura J, et al. Among authors: ruilope lm. Curr Opin Nephrol Hypertens. 2004 Sep;13(5):495-500. doi: 10.1097/00041552-200409000-00003. Curr Opin Nephrol Hypertens. 2004. PMID: 15300154 Review.

5

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.

Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, Unger T, Volpe M, Waeber B, Zannad F. Ruilope LM, et al. Blood Press. 2005;14(4):196-209. doi: 10.1080/08037050500230227. Blood Press. 2005. PMID: 16126553 Review.

6

Chronic kidney disease as a situation of high added risk in hypertensive patients.

Segura J, García-Donaire JA, Praga M, Ruilope LM. Segura J, et al. Among authors: ruilope lm. J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S136-40. doi: 10.1681/ASN.2005121330. J Am Soc Nephrol. 2006. PMID: 16565238 Review.

7

Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.

Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, Raz I, Voors AA, Dechamplain J, Weber MA. Bakris GL, et al. J Hum Hypertens. 2006 Sep;20(9):693-700. doi: 10.1038/sj.jhh.1002050. Epub 2006 May 18. J Hum Hypertens. 2006. PMID: 16710287 Clinical Trial.

8

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Bakris GL, et al. Among authors: ruilope lm. J Hypertens. 2006 Oct;24(10):2047-55. doi: 10.1097/01.hjh.0000244955.39491.88. J Hypertens. 2006. PMID: 16957566 Clinical Trial.

9

The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.

Ruilope L, Kjeldsen SE, de la Sierra A, Mancia G, Ruggenenti P, Stergiou GS, Bakris GL, Giles TD. Ruilope L, et al. Blood Press. 2007;16(2):72-9. doi: 10.1080/08037050701338985. Blood Press. 2007. PMID: 17612904 Review.

10

Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.

Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Bakris GL, et al. Kidney Int. 2007 Oct;72(7):879-85. doi: 10.1038/sj.ki.5002455. Epub 2007 Aug 1. Kidney Int. 2007. PMID: 17667984 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

770 results

Search Page